Loading clinical trials...
Loading clinical trials...
To determine whether treatment of patients who have toxic epidermal necrolysis with a drug called remicaide increases the number of patients who are alive 30 days laters.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Loyola University
NCT04711200 · Epidermal Necrolysis, Lyell Syndrome, and more
NCT06474078 · Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis
NCT02319616 · Toxic Epidermal Necrolysis
NCT02574988 · Steven-Johnson Syndrome, Toxic Epidermal Necrolysis, and more
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions